You are here

2009

Original articles

Vieyres G., Angus A.G., Haberstroh A., Baumert T.F., Dubuisson J., Patel A.H. Rapid synchronization of Hepatitis C Virus infection by magnetic adsorption. J. Virol. Methods., 2009, 157, 69-79.

Tian Z.F., Shen H., Fu X.H., Chen Y.C., Blum H.E., Baumert T.F., Zhao X.P. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World. J. Gastroenterol., 2009, 15, 240-4.

Pastor R., Habersetzer F., Fafi-Kremer S., Doffoel M., Baumert T.F., Gut J.P., Stoll-Keller F., Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment naïve patients. World. J. Gastroenterol., 2009, 15, 753-5.

Sava I.G., Zhang F., Toma I., Theilacker C., Li B., Baumert T.F., Holst O., Linhardt R.J., Huebner J. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J. Biol. Chem., 2009, 284, 18194-201.

Gondois-Rey F., Dental C., Halfon P., Baumert T.F., Olive D., Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS ONE, 2009, 4, e4319.

Weseslindtner L., Neumann-Haefelin C., Viazov S., Haberstroh A., Kletzmayr J., Aberle J.H., Timm J., Ross S.R., Klauser-Braun R., Baumert T.F., Roggendorf M., Thimme R., Holzmann H. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. J. Hepatol., 2009, 50, 693-704.

Hoffmann M., Zeisel M.B., Jilg N., Paranhos-Baccala G., Stoll-Keller F., Wakita T., Hafkemeyer P., Blum H.E., Barth H., Henneke P., Baumert T.F. Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J. Innate Immun., 2009, 1, 446-454.

Mello I.M., Thumann C., Schvoerer E., Soulier E., Pinho J.R., Silvestre D.A., Queiroz A.T., Wolf P., Baumert T.F., Stoll-Keller F., Pereira C.A. Conservation of hepatitis C virus non-structural protein 3 amino acid sequence in viral isolates during liver transplantation. J. Viral. Hepat., 2009, 16, 732-7.

Amiel C., Legoff J., Lescure F.X., Coste-Burel M., Deback C., Fafi-Kremer S., Gueudin M., Lafon M.E., Leruez-Ville M., Mengelle C., Payan C., Pillet S. Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study. J. Acquir. Immune Defic. Syndr., 2009, 50, 427-9.

Kremer S., Matern J.F., Bilger K., Lioure B., Fornecker Y., Stoll-Keller F., Namer I.J., Dieteman J.L., Fafi-Kremer S. EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation. J. Neuroradiol., 2009, 37, 189-91.

Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J.S., Quivy V., Vanhulle C., Lamine A., Vaira D., Demonte D., Martinelli V., Veithen E., Cherrier T., Avettand V., Poutrel S., Piette J., De Launoit Y., Moutschen M., Burny A., Rouzioux C., De Wit S., Herbein G., Rohr O., Collette Y., Lambotte O., Clumeck N., Van Lint C. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostatin: implications for treatment of latent infection. PLoS One, 2009, 4, e6093.

Himmelsbach K., Sauter D., Baumert T., Ludwig L., Blum H., Hildt E. New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV replication. Gut, 2009, 58, 1644-53.

Cherrier T., Suzanne S., Redel L., Calao M., Marban C., Samah B., Mukerjee R., Schwartz C., Gras G., Sawaya B.E., Zeichner S.L., Aunis D., Van Lint C., Rohr O. p21 (WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogène, 2009, 28, 3380-9.

Fenyö E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., Donners H., Heyndrickx L., Alcami J., Bongertz V., Jassoy C., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Sattentau Q., Schuitemaker H., Sutthent R., Wrin T., Scarlatti G. International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLoS One, 2009, 4:e4505.

Lambotte O., Ferrari G., Moog C., Venet A., Yates N.L., Liao H-X, Parks R., Hicks C.B., Tomaras G., Montefiori D., Haynes B.F., Delfraissy J.F. Heterogeneous neutralizing antibody and Antibody-Dependent Cell Cytotoxicity responses in HIV-1 Elite Controllers, AIDS, 2009, 15, 897-906.

Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., Reynes J.M., Lopalco L., Bomsel M. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol., 2009, 2, 412-26.

Perez-Anes A., Spataro G., Coppel Y., Moog C., Blanzat M., Turrin C., Caminade A., Lattes I.R., Majoral J.P. Phosphonate terminated PPH dendrimers: influence of pendant alkyl chains on the in vitro anti-HIV-1 properties. Org. Biomol. Chem., 2009, 7, 3491-3498.

Corellou F., Schwartz C., Motta J.P., Djouani-Tahri E.B., Sanchez F., Bouget F.Y. Clocks in the Green Lineage: Comparative Functional Analysis of the Circadian Architecture of the Picoeukaryote Ostreococcus. Plant Cell., 2009, 21, 3436-49.

Legrand-Abravanel F., Colson P., Leguillou-Guillemette H., Alric L., Ravaux I., Lunel-Fabiani F., Bouviers-Alias M., Trimoulet P., Chaix M.L., Hezode C., Foucher J., Fontaine H., Roque-Afonso A.M., Gassin M., Schvoerer E., Gaudy C., Roche B., Doffoel M., D’alteroche L., Vallet S., Baazia Y., Pozzetto B., Thibault V., Nousbaum J.B., Roulot D., Coppere H., Poinard T., Payan C., Izopet J. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol., 2009, 81, 2029-35.

Bouzgarrou N., Hassen E., Mahfoudh W., Gabbouj S., Schvoerer E., Ben Yahia A., Ben Mami N., Triki H., Chouchane L. NS5A (ISDR-V3) region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy. J. Med. Virol., 2009, 81, 2021-8.

Brehant O., Pessaux P., Regenet N., Tuech J.J., Panaro F., Mantion G., Tassetti V., Lehur P.A., Arnaud J.P. Healing of stoma orifices: multicenter, prospective, randomized study comparing calcium alginate mesh and polyvidone iodine mesh. World J. Surg., 2009, 33, 1795-801.

Oussoultzoglou E., Romain B., Panaro F., Rosso E., Pessaux P., Bachellier P., Jaeck D. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann. Surg., 2009, 249, 879-86.

Pessaux P., Panaro F. Advantages of the first-step totally laparoscopic approach in 2-staged hepatectomy for colorectal synchronous liver metastasis. Surgery, 2009, 145, 453.

Zacharias T., Oussoultzoglou E., Jaeck D., Pessaux P., Bachellier P. Surgery for recurrence of periampullary malignancies. J. Gastrointest. Surg., 2009, 13, 760-7.

Reviews, editorials etc.

Schuster C., Baumert T.F. EWI-2wint-A host cell factor inhibiting hepatitis C virus entry. J. Hepatol., 2009, 50, 222-4.

Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines, 2009, 8, 333-45.

Zeisel M.B., Barth H., Schuster C., Baumert T.F. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Frontiers in Biosciences, 2009, 14, 3274-85.

Lambotin M., Stoll-Keller F., Baumert T.F. Host responses to hepatitis C virus infection: gene expression profiles and viral pathogenesis. In: “Host Gene Responses to RNA Viral Infection“, (D. Yang ed.), Word Scientific Publishing New Jersey, 2009, p.471-494.

Pfeffer S., Baumert T.F. Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. J. Hepatol., 2009, 51, 606-9.

Zeisel M.B., Baumert T.F. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol., 2009, 4, 511-7.

Eyre N.S., Baumert T.F., Beard M.R. Closing the gap: the tight junction protein occluding and hepatitis C virus entry. Hepatology, 2009, 49, 1770-2.

Habersetzer F., Baumert T.F., Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr. Opin. Mol. Ther., 2009, 11, 456-62.

Zeisel M.B., Fafi-Kremer S., Robinet E., Habersetzer F., Baumert T.F., Stoll-Keller F. Adaptive Immunity to hepatitis C virus. Viruses, 2009, 1, 276-297.

Forthall D., Moog C. Fc receptor-mediated antiviral antibodies. Current opinion in HIV and AIDS, 2009, 4, 388-393.

Schvoerer E., Gut J.P., Stoll-Keller F. Effets des changements climatiques sur les maladies virales : quels sont les risques potentiels ? Virologie - Revue française des enseignants de virologie. 2009, 13, 1-6.

Holl V., Peressin M., Moog C. Antibody mediated Fcg receptor-based mechanisms of HIV inhibition: Recent findings and new vaccination strategies. Viruses, 2009, 1, 1265-1294.